Eyas Raddad

A Phase I Trial of LY2510924, a CXCR4 Peptide Antagonist, in Patients with Advanced Cancer

Matthew D. Galsky, Nicholas J. Vogelzang, Paul Conkling et al. · Clinical Cancer Research · 2014 · 109 citations

Short‐term administration of the glucagon receptor antagonist <scp>LY2409021</scp> lowers blood glucose in healthy people and in those with type 2 diabetes

Raymond P. Kelly, Parag Garhyan, Eyas Raddad et al. · Diabetes Obesity and Metabolism · 2015 · 107 citations

A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced Cancer

Michael Michael, Yung‐Jue Bang, Young Suk Park et al. · Targeted Oncology · 2017 · 80 citations

Advanced Cancer, Medicine, Pharmacology +7

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the CGRP Binding Monoclonal Antibody LY2951742 (Galcanezumab) in Healthy Volunteers

David Monteith, Emily C. Collins, Corinne Vandermeulen et al. · Frontiers in Pharmacology · 2017 · 64 citations · Full text

Discovery of 6-(4-{[5-Cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl]methoxy}piperidin-1-yl)-1-methyl-1<i>H</i>-indole-3-carboxylic Acid: A Novel FXR Agonist for the Treatment of Dyslipidemia

Michaël Génin, Ana B. Bueno, Javier Agejas Francisco et al. · Journal of Medicinal Chemistry · 2015 · 57 citations · Full text

Pharmaceutical Science, Selective Fxr Agonist, Farnesoid X Receptor +18